Anni Lotte Kirstine Sonderbjerg Pedersen, EVP and Chief Administrative Officer of Ascendis Pharma A/S (NASDAQ:ASND), filed a Form 4 on November 18, 2026, disclosing transactions in ordinary shares on November 17, 2026.
Key Highlights
- Warrant exercise: Sonderbjerg exercised 20,000 fully vested warrants at a conversion price of $37.18 per share on November 17, 2026.
- Sale of shares: 20,000 ordinary shares were disposed of at a price of $263.886 per share on the same date.
- Post-transaction ownership: Following the transactions, Sonderbjerg directly beneficially owns 19,460 ordinary shares.
- Warrants extinguished: The 20,000 warrants exercised carried an expiration date of December 12, 2027, and zero warrants of this series remain following the transaction.
- Filing role: Sonderbjerg is identified in the filing as EVP and Chief Administrative Officer of Ascendis Pharma A/S.
Sonderbjerg's November 2026 Warrant Exercise and Share Sale at Ascendis Pharma
According to the Form 4 filing, Anni Lotte Kirstine Sonderbjerg Pedersen, identified as EVP and Chief Administrative Officer of Ascendis Pharma A/S (NASDAQ:ASND), reported two transactions in the company's ordinary shares on November 17, 2026. The filing was submitted on November 18, 2026, by Michael Wolff Jensen as attorney-in-fact for Lotte Sonderbjerg.
The first transaction, coded "M," reflects the exercise of 20,000 warrants, acquiring 20,000 ordinary shares at a conversion or exercise price of $37.18 per share. The filing states that the warrants were fully vested and exercisable, and carried an expiration date of December 12, 2027. Following this exercise, the filing reports no remaining warrants of this series in Sonderbjerg's beneficial ownership. Prior to any disposition, the exercise brought her directly held ordinary shares to 39,460.
The second transaction, coded "S," records the sale of 20,000 ordinary shares at a price of $263.886 per share. After both transactions, the filing reports that Sonderbjerg directly beneficially owns 19,460 ordinary shares. Both the acquired and disposed shares are described as held directly. The filing was made by one reporting person and is not indicated as an amendment.
What Was Disclosed
The filing discloses that Ascendis Pharma's EVP and Chief Administrative Officer exercised 20,000 warrants at $37.18 per share and sold 20,000 ordinary shares at $263.886 per share on November 17, 2026, leaving a directly held balance of 19,460 ordinary shares.



Please wait processing your request...